The Sulfasalazine market is estimated to be valued at US$ 2.01 Bn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview

Sulfasalazine is a drug that is used to treat ulcerative colitis and rheumatoid arthritis. It works by suppressing the immune system and reducing swelling, pain, and damage in the joints. Sulfasalazine comes as delayed-release tablets and extended-release tablets to take by mouth.

Market Dynamics

The growth of the Sulfasalazine Market Size is attributed to rising prevalence of ulcerative colitis and rheumatoid arthritis globally over the forecast period. According to the National Psoriasis Foundation, around 7.5 million Americans have psoriasis, and 10-30% of those individuals develop psoriatic arthritis. Furthermore, increasing geriatric population are more prone to developing rheumatoid arthritis is also expected to drive the market growth.

Additionally, ongoing research and development activities to develop advanced drug delivery systems for sulfasalazine is also expected to offer lucrative growth opportunities for players in the sulfasalazine market. For instance, in 2022, researchers developed pH-responsive microspheres for colon targeted delivery of sulfasalazine to treat ulcerative colitis, which demonstrated sustained release of drug for over 24 hours.

SWOT Analysis

Strength: Sulfasalazine has strong anti-inflammatory properties that help treat many autoimmune disorders like rheumatoid arthritis effectively. It is available generically at lower prices making it affordable for many patients. The drug has a well established safety profile from decades of clinical use.

Weakness: Sulfasalazine has various side effects like nausea, vomiting, loss of appetite etc. if not taken correctly as prescribed. It may also cause serious blood disorders in some patients.

Opportunity: Increasing prevalence of autoimmune disorders like rheumatoid arthritis and ulcerative colitis is driving the need for affordable treatment options. Emerging economies with large patient pools present significant market potential.

Threats: Stiff competition from newer biologic disease modifying anti-rheumatic drugs. Patent expiries of major drugs may impact the market.

Key Takeaways

The global sulfasalazine market is expected to witness high growth, exhibiting CAGR of 5.7% over the forecast period, due to increasing prevalence of autoimmune disorders like rheumatoid arthritis and ulcerative colitis. As per reports, the global market size for sulfasalazine touched US$ 2.01 Bn in 2023.

The North American region currently dominates the sulfasalazine market owing to growing patient population, availability of advanced healthcare facilities and favorable reimbursement policies. However, Asia Pacific region is projected to exhibit fastest growth during the forecast period driven by expanding medical infrastructure, low-cost treatments and large pool of patients in emerging countries like India and China.

Key players operating in the sulfasalazine market are Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy's Laboratories, Zydus Cadila, Sun Pharmaceutical Industries, Aspen Pharmacare, Apotex Inc., Sandoz (a division of Novartis), Lupin Limited. The market is characterized by intense competition among these major players based on product offerings and pricing.

Read Our More Blogs : https://www.pressreleasebulletin.com/sulfasalazine-market-analysis-growth-forecast-outlook-2023-2030/